These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 15822682)
1. Circulating levels of prolactin in breast cancer patients. Mujagić Z; Mujagić H; Prnjavorac B Med Arh; 2005; 59(1):33-5. PubMed ID: 15822682 [TBL] [Abstract][Full Text] [Related]
2. The relationship between circulating carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients. Mujagić Z; Mujagic H; Prnjavorac B Med Arh; 2004; 58(1):23-6. PubMed ID: 15017899 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic usefulness of serum carcinoembryonic antigen determinations in breast cancer patients. Mujagić Z; Mujagić H Bosn J Basic Med Sci; 2003 May; 3(2):30-4. PubMed ID: 16223370 [TBL] [Abstract][Full Text] [Related]
4. Prolactin serum level in patients with breast cancer. Cohen AD; Cohen Y; Maislos M; Buskila D Isr Med Assoc J; 2000 Apr; 2(4):287-9. PubMed ID: 10804904 [TBL] [Abstract][Full Text] [Related]
5. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni GJ Neuro Endocrinol Lett; 2001; 22(1):27-9. PubMed ID: 11335876 [TBL] [Abstract][Full Text] [Related]
7. Importance of serum prolactin determination in metastatic breast cancer patients. Mujagić Z; Mujagić H Croat Med J; 2004 Apr; 45(2):176-80. PubMed ID: 15103755 [TBL] [Abstract][Full Text] [Related]
8. Decreased serum miR-181a is a potential new tool for breast cancer screening. Guo LJ; Zhang QY Int J Mol Med; 2012 Sep; 30(3):680-6. PubMed ID: 22692639 [TBL] [Abstract][Full Text] [Related]
9. Relationship between PRL levels and steroid receptors in breast cancer. Marugo M; Fazzuoli L; Bernasconi D; Berta S; Giordano G Anticancer Res; 1988; 8(4):819-23. PubMed ID: 3178171 [TBL] [Abstract][Full Text] [Related]
10. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247 [TBL] [Abstract][Full Text] [Related]
11. Association of prolactin and its receptor gene regions with familial breast cancer. Vaclavicek A; Hemminki K; Bartram CR; Wagner K; Wappenschmidt B; Meindl A; Schmutzler RK; Klaes R; Untch M; Burwinkel B; Försti A J Clin Endocrinol Metab; 2006 Apr; 91(4):1513-9. PubMed ID: 16434456 [TBL] [Abstract][Full Text] [Related]
12. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments. Pannuti F; Martoni A; Farabegoli G; Piana E Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487 [TBL] [Abstract][Full Text] [Related]
13. Thyroid-stimulating hormone and prolactin levels in breast cancer. Aldinger KA; Schultz PN; Blumenschein GR; Samaan NA Arch Intern Med; 1978 Nov; 138(11):1638-41. PubMed ID: 102267 [TBL] [Abstract][Full Text] [Related]
14. Elevated growth hormone levels in sera from breast cancer patients. Emerman JT; Leahy M; Gout PW; Bruchovsky N Horm Metab Res; 1985 Aug; 17(8):421-4. PubMed ID: 4054832 [TBL] [Abstract][Full Text] [Related]
15. Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay. Rose DP; Berke B; Cohen LA Horm Metab Res; 1988 Jan; 20(1):49-53. PubMed ID: 3371857 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer. Frontini L; Lissoni P; Vaghi M; Perego MS; Pescia S; Ardizzoia A; Gardani G Anticancer Res; 2004; 24(6):4223-6. PubMed ID: 15736476 [TBL] [Abstract][Full Text] [Related]
17. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C J BUON; 2009; 14(3):463-72. PubMed ID: 19810140 [TBL] [Abstract][Full Text] [Related]
18. Detection of circulating tumor cells in breast cancer patients utilizing multiparameter flow cytometry and assessment of the prognosis of patients in different CTCs levels. Hu Y; Fan L; Zheng J; Cui R; Liu W; He Y; Li X; Huang S Cytometry A; 2010 Mar; 77(3):213-9. PubMed ID: 20169594 [TBL] [Abstract][Full Text] [Related]
19. HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer. Lissoni P; Messina G; Rovelli F; Brivio F; Fumagalli L; Villa S; Bartolacelli E In Vivo; 2009; 23(6):987-9. PubMed ID: 20023245 [TBL] [Abstract][Full Text] [Related]
20. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. Tworoger SS; Eliassen AH; Sluss P; Hankinson SE J Clin Oncol; 2007 Apr; 25(12):1482-8. PubMed ID: 17372279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]